Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 7/20 | 0.41 |
| ▸ | CES1 | P23141 | 5/20 | 0.41 |
| ▸ | CES2 | O00748 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5196923 | 1.00 | MAPT (0.48) | MAPTGPR84CA2FAAHCES1 | |
| SCHEMBL5194151 | 1.00 | MAPT (0.48) | MAPTGPR84CA2FAAHCES1 | |
| SCHEMBL5197299 | 1.00 | MAPT (0.48) | MAPTGPR84CA2FAAHCES1 | |
| SCHEMBL5195926 | 0.98 | MAPT (0.46) | MAPTGPR84CA2FAAHCES1 | |
| SCHEMBL5195729 | 0.92 | CA2 (0.41) | MAPTCA2FAAHCES1CES2 | |
| SCHEMBL6913715 | 0.91 | MAPT (0.41) | MAPTGPR84CA2FAAHCES1 | |
| SCHEMBL5196980 | 0.84 | CHRM1 (0.34) | MAPTCA2FAAH | |
| SCHEMBL23554231 | 0.79 | GPR84 (0.63) | GPR84CA2FAAHFFAR1 | |
| SCHEMBL15374693 | 0.79 | GPR84 (0.63) | GPR84CA2FAAHFFAR1 | |
| SCHEMBL8406822 | 0.79 | GPR84 (0.62) | MAPTGPR84MEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1403260-B1 | Optically active epoxy compounds and processes for their production | TOSOH CORP (JP) | 2007-08-08 | — | — | EP | disclosed |
| US-7169944-B2 | Optically active epoxy compounds and processes for their production | TOSOH CORPORATION (JP) | 2007-01-30 | — | — | US | disclosed |
| US-20040063979-A1 | Optically active epoxy compounds and processes for their production | TOSOH CORPORATION (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1403260-A2 | Optically active epoxy compounds and processes for their production | Tosoh Corporation (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063979-A1 | Optically active epoxy compounds and processes for their production | CYP51A1, CYP11B1, PTGES | MAPT 4136/4885GPR84 3095/4885CA2 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.